A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
暂无分享,去创建一个
R. Kaiser | R. Doebele | D. Camidge | G. Otterson | A. Traynor | P. Stopfer | S. Wind | P. Conkling | Yihua Zhao | Y. Zhao | R. Kaiser | Yihua Zhao
[1] R. Kaiser,et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] N. Hanna,et al. Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non–Small Cell Lung Cancer Patients , 2010, Clinical Cancer Research.
[3] S. Loibl,et al. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] R. Kaiser,et al. Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.
[5] W. Berdel,et al. An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma. , 2009, Anticancer research.
[6] P. Bunn,et al. Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells , 2009, Molecular Pharmacology.
[7] W. Sommergruber,et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. , 2008, Cancer research.
[8] M. Socinski,et al. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer , 2008 .
[9] Ping Yang,et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.
[10] L. Seymour,et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] H. Wakelee,et al. Role of Anti-angiogenesis Agents in Treating NSCLC: Focus on Bevacizumab and VEGFR Tyrosine Kinase Inhibitors , 2007, Current treatment options in oncology.
[12] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[13] N. Hanna,et al. Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[14] A R Padhani,et al. A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Peter Carmeliet,et al. Angiogenesis in life, disease and medicine , 2005, Nature.
[16] Jürgen Hennig,et al. A clinical phase I, pharmacokinetic (PK), and pharmacodynamic study of twice daily BIBF 1120 in advanced cancer patients , 2005 .
[17] M. Kaneuchi,et al. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer , 2002, Cancer Chemotherapy and Pharmacology.
[18] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[19] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[20] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[21] S. Duffull,et al. Clinical Pharmacokinetics and Dose Optimisation of Carboplatin , 1997, Clinical pharmacokinetics.
[22] G. Bonadonna,et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] W. J. Vijgh. Clinical Pharmacokinetics of Carboplatin , 1991 .
[24] K. Kimura,et al. Clinical Pharmacokinetics of Carboplatin , 1988, Journal of clinical pharmacology.